Skip to main content
medichelpline
Join Free
Back to Drug Index
CardiovascularTOPICALGeneric

MYCOSTATIN

NYSTATIN

Standard Dose
100,000 UNITS/GM **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
Max Dose
Refer to approved labeling
Primary Use
Marketing status: Discontinued

Key Takeaways

  • Primary indication: Marketing status: Discontinued
  • Approval overview MYCOSTATIN is listed in Drugs@FDA under application 060578 (ANDA).
  • Marketing status: Discontinued Active ingredient NYSTATIN Form and strength POWDER;TOPICAL - 100,000 UNITS/GM **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Sponsor DELCOR ASSET CORP Submission history Latest submission status date: 1998-09-17 00:00:00.

Structured Monograph

Clinical summary

Approval overview MYCOSTATIN is listed in Drugs@FDA under application 060578 (ANDA). Marketing status: Discontinued Active ingredient NYSTATIN Form and strength POWDER;TOPICAL - 100,000 UNITS/GM **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Sponsor DELCOR ASSET CORP Submission history Latest submission status date: 1998-09-17 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Discontinued

Interaction Notes

  • No interaction notes stored yet.